[email protected]

国际临床研究杂志

International Journal of Clinical Research

您当前位置:首页 > 精选文章

International Journal of Clinical Research. 2024; 8: (9) ; 10.12208/j.ijcr.20240387 .

Clinical efficacy observation of moxifloxacin in the treatment of community-acquired pneumonia
莫西沙星治疗社区获得性肺炎的临床疗效观察

作者: 曹颖 *

北京市通州区张家湾社区卫生服务中心 北京

*通讯作者: 曹颖,单位:北京市通州区张家湾社区卫生服务中心 北京;

引用本文: 曹颖 莫西沙星治疗社区获得性肺炎的临床疗效观察[J]. 国际临床研究杂志, 2024; 8: (9) : 185-187.
Published: 2024/9/28 15:32:27

摘要

目的 研究莫西沙星治疗社区获得性肺炎的临床疗效观察。方法 抽取我院于2023年2月-2024年2月收治的58例社区获得性肺炎患者,按照所有患者进行分配,将其分为普通组(29例)与指导组(29例)。最后对其患者治疗效果情况、不良并发症情况进行统计分析。结果 经分析,指导组患者并发症发生情况为(20.83%)明显低于普通组患者为(54.16%),故有对比意义(P<0.05)。指导组患者治疗效果情况有显著改善,数据对比在统计学上具有明显差异(P<0.05)。结论 莫西沙星在治疗社区获得性肺炎方面具有使用简便、无需进行皮肤测试、一次性给药以及相对较高安全性等多项优势。因此,国内外权威的治疗指南都强烈推荐使用莫西沙星作为治疗所有社区获得性肺炎的首选药物。

关键词: 莫西沙星;社区获得性肺炎;临床疗效;观察

Abstract

Objective: To investigate the clinical efficacy of moxifloxacin in the treatment of community-acquired pneumonia. Method: A total of 58 patients with community-acquired pneumonia admitted to our hospital from February 2023 to February 2024 were selected and allocated into a control group (29 cases) and a guidance group (29 cases) according to the distribution of all patients. Finally, statistical analysis was conducted on the treatment effectiveness and adverse complications of the patients. Result: After analysis, the incidence of complications in the guidance group (20.83%) was significantly lower than that in the control group (54.16%), indicating a comparative significance (P<0.05). The treatment effect of the guidance group patients has significantly improved, and the data comparison shows significant statistical differences (P<0.05).
Conclusion  : Moxifloxacin has multiple advantages in the treatment of community-acquired pneumonia, including ease of use, no need for skin testing, one-time administration, and relatively high safety. Therefore, authoritative treatment guidelines both domestically and internationally strongly recommend the use of moxifloxacin as the preferred medication for the treatment of all community-acquired pneumonia.

Key words: Moxifloxacin; Community acquired pneumonia; Clinical efficacy; observation

参考文献 References

[1] 秦大翔,梁冰.莫西沙星联合利奈唑胺治疗老年社区获得性肺炎临床疗效及对免疫功能的影响[J].中国老年学杂志,2024,44(12):2856-2859.

[2] 余如华,徐蓉蓉,吴书清.奥马环素与莫西沙星治疗社区获得性肺炎的效果比较[J].中国医药导报,2024,21(17): 99-102.

[3] 肖瑜,杨娅.蓝芩口服液联合莫西沙星+氨溴索治疗社区获得性肺炎的临床观察[J].西藏医药,2023,44(05):136-138.

[4] 王珊珊,欧利军.莫西沙星序贯治疗老年社区获得性肺炎的临床效果[J].临床合理用药,2023,16(13):51-54.

[5] 娄梅梅,王海亮,徐兰霞.莫西沙星与左氧氟沙星联合哌拉西林/他唑巴坦治疗社区获得性肺炎的临床优势比较[J].临床合理用药,2023,16(07):70-73.

[6] 张琳琳,陈蕾,李春红,等.莫西沙星与左氧氟沙星治疗老年社区获得性肺炎患者的效果对比[J].中国药物滥用防治杂志,2022,28(07):941-945.

[7] 任明霞,赵皖京.清咳平喘颗粒联合莫西沙星治疗成人轻中度社区获得性肺炎临床观察[J].中草药,2022,53(11): 3410-3414.

[8] 庄海涛,许洋.痰热清注射液联合莫西沙星注射液治疗老年社区获得性肺炎的临床效果及对血清炎性因子的影响[J].临床合理用药杂志,2022,15(11):13-16.

[9] 廖天竺.莫西沙星治疗社区获得性肺炎临床效果研究[J].医学食疗与健康,2021,19(15):56-57.

[10] 邵瑞玲.莫西沙星与头孢哌酮对老年社区获得性肺炎患者的临床疗效比较[J].抗感染药学,2021,18(06):920-923.